Perioperative pembrolizumab demonstrates clinical benefit in locally advanced HNSCC



Summary

Perioperative pembrolizumab, combining neoadjuvant and adjuvant immunotherapy around surgery, shows promising clinical benefit in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Studies demonstrate improved pathological complete response rates with neoadjuvant pembrolizumab, indicating tumor shrinkage before surgery. Adjuvant pembrolizumab, following surgery and chemotherapy/radiation, further extends progression-free survival. This combined approach aims to improve outcomes by targeting the cancer cells before and after surgery, potentially reducing the risk of recurrence and improving long-term survival in this patient population. These findings suggest a new standard of care for eligible HNSCC patients.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!